Besides improving T-cell responses, ligand activation of galectin-9 in the tumor microenvironment of pancreatic ductal adenocarcinoma results in tolerogenic macrophage programming and adaptive immune suppression69. This evidence concerns the gene LGALS9 and pancreatic ductal adenocarcinoma.